Aya El-Taibany

Dr. Aya El-Taibany


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Molecules
Verified
Journal Article
Open access
PDF file
KKKathrin Kostka
Kathrin Kostka
VSViktoriya Sokolova
Viktoriya Sokolova
AEAya El-Taibany
Aya El-Taibany
BKBenedikt Kruse
Benedikt Kruse
DPDaniel Almeida Porada
Daniel Almeida Porada
Anthony AtalaAnthony Atala
Anthony Atala
Among brain tumors, glioblastoma (GBM) is very challenging to treat as chemotherapeutic drugs can only penetrate the brain to a limited extent due to the blood–brain barrier (BBB). Nanoparticles can be an attractive solution for the treatment of GBM as they can transport drugs across the BBB into the tumor. In this study, normal and GBM organoids comprising six brain cell types were developed and applied to study the uptake, BBB penetration, distribution, and efficacy of fluorescent, ultrasmall gold nanoparticles (AuTio-Dox-AF647s) conjugated with doxorubicin (Dox) and AlexaFluor-647-cadaverine (AF647) by confocal laser scanning microscopy (CLSM), using a mixture of dissolved doxorubicin and fluorescent AF647 molecules as a control. It was shown that the nanoparticles could easily penetrate the BBB and were found in normal and GBM organoids, while the dissolved Dox and AF647 molecules alone were unable to penetrate the BBB. Flow cytometry showed a reduction in glioblastoma cells after treatment with AuTio-Dox nanoparticles, as well as a higher uptake of these nanoparticles by GBM cells in the GBM model compared to astrocytes in the normal cell organoids. In summary, our results show that ultrasmall gold nanoparticles can serve as suitable carriers for the delivery of drugs into organoids to study BBB function.

10 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AEAya El-Taibany
Aya El-Taibany
PHParichehr Heydarian
Parichehr Heydarian
DPDaniel A. Porada
Daniel A. Porada
MSMichael C. Seeds
Michael C. Seeds
AAAnthony Atala
Anthony Atala
Multiple sclerosis affects a significant portion of the world’s adult population and is the most common nontraumatic neuroimmunology disorder. Although the specific etiology of multiple sclerosis remains unknown, it has been associated with autoimmune components. While current treatment options relieve some symptoms in MS patients, most are immunosuppressive and only delay the progression of the disease without conferring definitive curative measures. Hence, a thorough understanding of disease pathobiology, the contribution of the neurovascular unit (NVU), and biological body-on-a-chip systems that replicate the blood–brain barrier may open new horizons for the discovery of potential therapeutics for MS.